Pronunciation FLOOR-ə-LAN-ər ATCvet code QP53BE02 (WHO) Formula C22H17Cl2F6N3O3 | Trade names Bravecto Legal status US: ℞-onlyOTC (RU) Molar mass 556.29 g/mol | |
 | ||
Routes ofadministration By mouth (chewable tablets) Bioavailability 20–27%; reduced in the fasted state IUPAC ID 4-[(5R/S)-5-(3,5-Dichlorophenyl)-4,5-dihydro-5-trifluoromethyl-1,2-oxazol-3-yl]-N-[2-oxo-2-(2,2,2-trifluoroethylamino)ethyl]-o-toluamide | ||
Fluralaner (INN) is a systemic insecticide and acaricide that is administered orally. The U.S. Food and Drug Administration (FDA) approved it under the trade name Bravecto for flea treatment in dogs in May 2014. The EU approved the drug in February 2014. Australia approved its use for sale as a flea and tick control treatment.
Mode of action
Fluralaner is an inhibitor of the arthropod nervous system. Fluralaner inhibits γ-aminobutyric acid (GABA)-gated chloride channels (GABACls) and L-glutamate-gated chloride channels (GluCls). Potency of fluralaner is comparable to fipronil (a phenylpyrazole ectoparasiticide).
References
Fluralaner Wikipedia(Text) CC BY-SA